Extendicare Inc.
TSX:EXE.TOMedical - Care Facilities
+$0.86 today
- Market cap
- $2.74B
- Beta
- 1.16
- P/E (TTM)
- 26.4
- EPS (TTM)
- $1.28
- Dividend yield
- 1.51%
Volume 0.86M
Average 0.34M
EXE.TO Pre-Tax Margin
Income before tax as a percentage of revenue.
Extendicare Inc.TSX: EXE.TO
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin narrows to 6.2%
Pre-tax margin was 6.2% in Q2 FY2026, down 4.6 pp from a year earlier. On a trailing-twelve-month basis it was 7.9%, up 0.7 pp year over year. Over 3 fiscal years it widened by 8.2 pp.
Context
- Pre-tax margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 7.8%
- Year-over-year change
- +1.0pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.8% | +1.0pp |
| FY2024 | 2024-12-31 | 6.8% | +3.4pp |
| FY2023 | 2023-12-31 | 3.4% | +3.8pp |
| FY2022 | 2022-12-31 | -0.4% | -1.6pp |
| FY2021 | 2021-12-31 | 1.2% | — |
Pre-Tax Margin vs competitors
How EXE.TO compares with its peers on the latest reported figures
- EXE.TO's LTM Jun 2026 pre-tax margin of 7.9% is the 2nd highest of the 7 companies compared; the peer median is 2.1%.
- Its year-over-year change of +0.7 pp is the 4th highest of 7, against a peer median of +1.1 pp.
- Over three fiscal years its change of +8.2 pp compares with a peer median of +7.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 18.4% | +1.7 pp | +11.5 pp | |
| LTM Jun 2026 | 7.9% | +0.7 pp | +8.2 pp | |
| LTM Sep 2026 | 6.1% | +0.5 pp | +4.6 pp | |
| LTM Mar 2026 | 2.8% | +8.3 pp | -2.8 pp | |
| LTM Mar 2026 | 1.3% | +2.3 pp | +10.3 pp | |
| LTM Mar 2026 | -4.2% | -41.8 pp | +127.8 pp | |
| LTM Feb 2026 | -169.8% | -54.6 pp | -210.2 pp | |
| Peer median (excluding EXE.TO) | 2.1% | +1.1 pp | +7.5 pp | |
Competitors are the stored peer set for EXE.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.22B | 1.3B | 1.47B | 1.66B |
| Cost of Revenue | 1.05B | 1.14B | 1.14B | 1.3B | 1.46B |
| Gross Profit | 115.61M | 76.83M | 167.62M | 168M | 199.59M |
| Gross Margin | 9.9% | 6.3% | 12.8% | 11.5% | 12.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 69.79M | 51.08M | 55.84M | 1.2B | 1.36B |
| Operating Expenses | 52.43M | 50.78M | 55.84M | 56.94M | 61.22M |
| Depreciation & Amortization | 38.57M | 32.12M | 32.23M | 33.34M | 37.25M |
| EBITDA | 75M | 49.33M | 98.63M | 155.27M | 175.61M |
| EBITDA Margin | 6.4% | 4.0% | 7.6% | 10.6% | 10.6% |
| Operating Income | 49.71M | 20.99M | 62.96M | 111.21M | 138.37M |
| Operating Margin | 4.3% | 1.7% | 4.8% | 7.6% | 8.3% |
| Interest Income | 1.87M | 5.02M | 6.19M | 7.04M | 5.73M |
| Interest Expense | 22.45M | 21.7M | 21.6M | 21.1M | 19.23M |
| Other Income / Expenses | (35.72M) | (25.48M) | (18.16M) | (11.35M) | (8.26M) |
| Income Before Tax | 13.99M | (4.5M) | 44.8M | 99.86M | 130.1M |
| Pre-Tax Margin | 1.2% | -0.4% | 3.4% | 6.8% | 7.8% |
| Income Tax Expense | 6.48M | 15K | 10.82M | 24.65M | 33.45M |
| Net Income | 11.5M | 69.55M | 33.98M | 75.21M | 96.66M |
| Net Margin | 1.0% | 5.7% | 2.6% | 5.1% | 5.8% |
| EPS (Basic) | 0.13 | 0.85 | 0.40 | 0.97 | 1.13 |
| EPS (Diluted) | 0.13 | 0.85 | 0.40 | 0.86 | 1.11 |
| Weighted Avg Shares | 89.99M | 89.01M | 84.99M | 84.22M | 85.4M |
| Weighted Avg Shares (Diluted) | 100.9M | 89.01M | 84.99M | 95.36M | 86.84M |
Extendicare Inc.
TSX:EXE.TO
Intrinsic Alpha fair value
Locked
Current Price
$28.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.